Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Servier’s Voranigo Skips November Listing; GSK, BMS Drugs Also Absent
Servier’s isocitrate dehydrogenase (IDH)-targeted glioma therapy Voranigo (vorasidenib) approved in September will not be included in Japan’s new drug price listings taking effect November 12, Jiho has learned. According to the company’s Japan arm, Nihon Servier, it decided not to…
To read the full story
Related Article
- Voranigo and More Meds Missing from April Listing Slate; Servier Plans Packaging Change
April 10, 2026
- Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
- GSK’s Exdensur, Lilly’s Inluriyo Missing from March Listing Roster
March 12, 2026
- Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen
November 6, 2025
- GSK’s Blenrep, BMS’s Inrebic Absent from October Listing Roster
October 17, 2025
REGULATORY
- Kampo Industry Calls for Predictable Drug Pricing to Support Stable Supply
June 23, 2026
- Yoshida Pharma Plant Hit with Improvement Order over Testing Violations
June 23, 2026
- Carvykti Earlier Use Up for Japan Panel Review on June 29
June 23, 2026
- Japan Approves Wegovy MASH Use, AstraZeneca’s Etcamah, Others
June 22, 2026
- Japan on Alert over US MFN Drug Pricing Policy: Health Minister
June 22, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…